Microglial HCAR2 as a therapeutic target for tau pathology in alzheimer's disease
Research platform targeting the niacin receptor HCAR2 (GPR109A) in microglia to promote neuroprotective activity against tau pathology in Alzheimer's disease. Leverages an FDA-approved niacin formulation and conditional ...